Costs and cost-efficacy analysis of the preferred treatments by GESIDA/National plan for AIDS for the initial antiretroviral therapy in adult human Immunodeficiency virus (HIV) infected patients in 2012;Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA/Plan Nacional sobre el Sida en 2012 para el tratamiento antirretroviral inicial en adultos infectados por el virus de la inmunodeficiencia humana (VIH)

Enfermedades Infecciosas y Microbiologia Clinica

Volumn 30, Issue 6, 2012, Pages 283-293

  Blasco, Antonio Javier ^a   Arribas, José Ramón ^b   Boix, Vicente ^c   Clotet, Bonaventura ^d   Domingo, Pere ^d   González García, Juan ^b   Knobel, Hernando ^e   López, Juan Carlos ^f   Llibre, Josep M ^d   Lozano, Fernando ^g   Miró, José M ^h   Podzamczer, Daniel ⁱ   Santamaría, Juan Miguel ^j   Tuset, Montserrat ^k   Zamora, Laura ^h   Lázaro, Pablo ^a   Gatell, Josep M ^h  

^a Tecnicas Avanzadas de Investigacion en Servicios de Salud TAISS   (Spain)

^b HOSPITAL UNIVERSITARIO LA PAZ   (Spain)

^c HOSPITAL GENERAL UNIVERSITARIO DE ALICANTE   (Spain)

^d UNIVERSITAT AUTÒNOMA DE BARCELONA   (Spain)

^e HOSPITAL DEL MAR   (Spain)

^f HOSPITAL GENERAL UNIVERSITARIO GREGORIO MARAÑÓN   (Spain)

^g HOSPITAL UNIVERSITARIO DE VALME   (Spain)

^h UNIVERSITY OF BARCELONA   (Spain)

ⁱ HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^j HOSPITAL DE BASURTO   (Spain)

^k HOSPITAL CLÍNIC   (Spain)

more..

Author keywords

Adult human Immunodeficiency virus (HIV); AIDS; Antiretrovirals; Cost; Efficacy; Efficiency; Therapy

Indexed keywords

ABACAVIR PLUS LAMIVUDINE; ATAZANAVIR; DARUNAVIR; EFAVIRENZ; EFAVIRENZ PLUS EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; EMTRICITABINE PLUS TENOFOVIR DISOPROXIL; HLA B ANTIGEN; HLA B5701 ANTIGEN; LOPINAVIR; NEVIRAPINE; RALTEGRAVIR; UNCLASSIFIED DRUG;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ARTICLE; COST; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG RESISTANCE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; VIRUS LOAD;

ANTI-HIV AGENTS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CLINICAL PROTOCOLS; CLINICAL TRIALS AS TOPIC; COST-BENEFIT ANALYSIS; DECISION TREES; DISEASE MANAGEMENT; DRUG COSTS; DRUG RESISTANCE, VIRAL; DRUG THERAPY, COMBINATION; GENOTYPE; HEALTH EXPENDITURES; HIV INFECTIONS; HUMANS; MODELS, ECONOMIC; NATIONAL HEALTH PROGRAMS; PRACTICE GUIDELINES AS TOPIC; PRESCRIPTION FEES; SOCIETIES, MEDICAL; SPAIN;

EID: 84862877692     PISSN: 0213005X     EISSN: 15781852     Source Type: Journal    
DOI: 10.1016/j.eimc.2012.02.016     Document Type: Article

References (43)

1. F.J. Palella Jr., K.M. Delaney, A.C. Moorman, M.O. Loveless, J. Fuhrer, and G.A. Satten Declining morbidity and mortality among patients with advanced human immunodeficiency virus infection. HIV Outpatient Study Investigators N Engl J Med 338 1998 853 860 (Pubitemid 28135961)
2. A. Mocroft, S. Vella, T.L. Benfield, A. Chiesi, V. Miller, and P. Gargalianos Changing patterns of mortality across Europe in patients infected with HIV-1. EuroSIDA Study Gro up Lancet 352 1998 1725 1730 (Pubitemid 28534954)
3. B. Autran, G. Carcelain, T.S. Li, C. Blanc, D. Mathez, and R. Tubiana Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease Science 277 1997 112 116 (Pubitemid 27450659)
4. A.D. Kelleher, A. Carr, J. Zaunders, and D.A. Cooper Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir J Infect Dis 173 1996 321 329
5. J.J. Lok, R.J. Bosch, C.A. Benson, A.C. Collier, G.K. Robbins, and R.W. Shafer Long-term increase in CD4+ T-cell counts during combination antiretroviral therapy for HIV-1 infection AIDS 24 2010 1867 1876
6. F. Garcia, E. Lazzari de, M. Plana, P. Castro, G. Mestre, and M. Nomdedeu Long-term CD4+ T-cell response to highly active antiretroviral therapy according to baseline CD4+ T-cell count J Acquir Immune Defic Syndr 36 2004 702 713 (Pubitemid 38685964)
7. N. Lohse, A.B. Hansen, G. Pedersen, G. Kronborg, J. Gerstoft, and H.T. Sorensen Survival of persons with and without HIV infection in Denmark, 1995-2005 Ann Intern Med 146 2007 87 95 (Pubitemid 351640011)
8. M. May, M. Gompels, V. Delpech, K. Porter, F. Post, and M. Johnson Impact of late diagnosis and treatment on life expectancy in people with HIV-1: UK Collaborative HIV Cohort (UK CHIC) Study BMJ 343 2011 d6016
9. E.J. Beck, S. Mandalia, M. Gaudreault, C. Brewer, H. Zowall, and N. Gilmore The cost-effectiveness of highly active antiretroviral therapy. Canada 1991-2001 AIDS 18 2004 2411 2418 (Pubitemid 40065908)
10. K.A. Freedberg, E. Losina, M.C. Weinstein, A.D. Paltiel, C.J. Cohen, and G.R. Seage The cost effectiveness of combination antiretroviral therapy for HIV disease N Engl J Med 344 2001 824 831 (Pubitemid 32222162)
11. S.J. Goldie, Y. Yazdanpanah, E. Losina, M.C. Weinstein, X. Anglaret, and R.P. Walensky Cost-effectiveness of HIV treatment in resource-poor settings - the case of Cote d'Ivoire N Engl J Med 355 2006 1141 1153 (Pubitemid 44394920)
12. K.M. Johnston, A.R. Levy, V.D. Lima, R.S. Hogg, M.W. Tyndall, and P. Gustafson Expanding access to HAART: a cost-effective approach for treating and preventing HIV AIDS 24 2010 1929 1935
13. P.P. Sendi, H.C. Bucher, T. Harr, B.A. Craig, M. Schwietert, and D. Pfluger Cost effectiveness of highly active antiretroviral therapy in HIV-infected patients. Swiss HIV Cohort Study AIDS 13 1999 1115 1122 (Pubitemid 29361403)
14. Y. Yazdanpanah Costs associated with combination antirretroviral therapy in HIV-infected patients J Antimicro Chemother 53 2004 558 561 (Pubitemid 38499767)
15. E.J. Beck, S. Mandalia, R. Sangha, P. Sharott, M. Youle, and G. Baily The cost-effectiveness of early access to HIV services and starting cART in the UK 1996-2008 PLoS One 6 2011 e27830
16. K.M. Johnston, A.R. Levy, V.D. Lima, R.S. Hogg, M.W. Tyndall, and P. Gustafson Expanding access to HAART: a cost-effective approach for treating and preventing HIV AIDS 24 2010 1929 1935
17. S.P. Koenig, H. Bang, P. Severe, M.A. Jean Juste, A. Ambroise, and A. Edwards Cost-effectiveness of early versus standard antiretroviral therapy in HIV-infected adults in Haiti Plos Med 8 2011 e1001095
18. Panel de Expertos de GESIDA, Plan Nacional sobre el SIDA Documento de consenso de GESIDA/Plan Nacional sobre el Sida respecto al tratamiento antirretroviral en adultos infectados por el virus de la inmunodeficiencia humana (Actualización enero 2012) Enf Inf Microb Clin 30 2012 e1 e89
19. A.J. Blasco, J.R. Arribas, B. Clotet, P. Domingo, J. González- García, and J.C. López-Bernaldo Análisis de costes y de coste/eficacia de las pautas preferentes de GESIDA para el tratamiento antirretroviral inicial Enferm Infecc Microbiol Clin 29 2011 721 730
20. Real Decreto-ley 8/2010, de 20 de mayo, por el que se adoptan medidas extraordinarias para la reducción del déficit público. Boletín Oficial del Estado, n.° 126, 24 Mayo 2010.
21. Consejo General de Colegios Oficiales de Farmacéuticos. Portalfarma [consultado 2 Dici 2011]. Disponible en: https://botplusweb. portalfarma.com/
22. J.L. Lennox, E. DeJesus, A. Lazzarin, R.B. Pollard, J.V. Ramalho, and D.S. Berger Safety and efficacy of raltegravir-based versus efavirenz-based combination therapy in treatment-naive patients with HIV-1 infection: a multicentre, double-blind randomised controlled trial Lancet 374 2009 796 806
23. J.E. Gallant, E. DeJesus, J.R. Arribas, A.L. Pozniak, B. Gazzard, and R.E. Campo Tenofovir DF, emtricitabine, and efavirenz vs. zidovudine, lamivudine, and efavirenz for HIV N Engl J Med 354 2006 251 260 (Pubitemid 43113030)
24. R. Ortiz, E. DeJesus, H. Khanlou, E. Voronin, J. van Lunzen, and J. Andrade-Villanueva Efficacy and safety of once-daily darunavir/ritonavir versus lopinavir/ritonavir in treatment-naive HIV-1-infected patients at week 48 AIDS 22 2008 1389 1397
25. J.M. Molina, J. Andrade-Villanueva, J. Echevarria, P. Chetchotisakd, J. Corral, and N. David Once-daily atazanavir/ritonavir versus twice-daily lopinavir/ritonavir, each in combination with tenofovir and emtricitabine, for management of antiretroviral-naive HIV-1-infected patients: 48 week efficacy and safety results of the CASTLE study Lancet 372 2008 646 655
26. V. Soriano, K. Arasteh, H. Migrone, T. Lutz, M. Opravil, and J. Andrade-Villanueva Nevirapine versus atazanavir/ritonavir, each combined with tenofovir disoproxil fumarate/emtricitabine, in antiretroviral-naive HIV-1 patients: the ARTEN Trial Antivir Ther 16 2011 339 348
27. J. Gathe, B.A. da Silva, D.E. Cohen, M.R. Loutfy, D. Podzamczer, and R. Rubio A once-daily lopinavir/ritonavir-based regimen is non-inferior to twice-daily dosing and results in similar safety and tolerability in antiretroviral-naive subjects through 48 weeks J Acquir Immune Defic Syndr 50 2009 474 481
28. S. Walmsley, A. Avihingsanon, J. Slim, D.J. Ward, K. Ruxrungtham, and J. Brunetta Gemini: a non-inferiority study of saquinavir/ritonavir versus lopinavir/ritonavir as initial HIV-1 therapy in adults J Acquir Immune Defic Syndr 50 2009 367 374
29. K.Y. Smith, D. Fine, P. Patel, N.C. Bellos, L. Sloan, and P. Lackey Efficacy and safety of abacavir/lamivudine compared to tenofovir/emtricitabine in combination with once-daily lopinavir/ritonavir through 48 weeks in the HEAT Study. Poster 774 The 15th Conference on Retroviruses and Opportunistic Infections (CROI), 3-6 February Boston, MA, USA 2008
30. J. Eron Jr., P. Yeni, J. Gathe Jr., V. Estrada, E. DeJesus, and S. Staszewski The KLEAN study of fosamprenavir-ritonavir versus lopinavir-ritonavir, each in combination with abacavir-lamivudine, for initial treatment of HIV infection over 48 weeks: a randomised non-inferiority trial Lancet 368 2006 476 482 (Pubitemid 44160731)
31. E. De Jesus, G. Herrera, E. Teofilo, J. Gerstoft, C.B. Buendia, and J.D. Brand Abacavir versus zidovudine combined with lamivudine and efavirenz, for the treatment of antiretroviral-naive HIV-infected adults Clin Infect Dis 39 2004 1038 1046 (Pubitemid 39313463)
32. J.M. Molina, P. Cahn, B. Grinsztejn, A. Lazzarin, A. Mills, and M. Saag Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial Lancet 378 2011 238 246
33. J.J. Eron Jr., J.K. Rockstroh, J. Reynes, J. Andrade-Villanueva, J.V. Ramalho-Madruga, and L.G. Bekker Raltegravir once daily or twice daily in previously untreated patients with HIV-1: a randomised, active-controlled, phase 3 non-inferiority trial Lancet Infect Dis 11 2011 907 915
34. J. Gathe, J. Andrade-Villanueva, S. Santiago, A. Horban, M. Nelson, and P. Cahn Efficacy and safety of nevirapine extended-release once daily versus nevirapine immediate-release twice-daily in treatment-naïve HIV-1-infected patients Antivir Ther 16 2011 759 769
35. J. Reynes, A. Lawal, F. Pulido, R. Soto-Malave, J. Gathe, and M. Tian Examination of Non-inferiority. Safety, and tolerability of lopinavir/ritonavir and raltegravir compared with lopinavir/ritonavir and tenofovir/emtricitabine in antiretroviral-naïve subjects: the PROGRESS Study, 48-week results HIV Clin Trials 12 2011 255 267
36. E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, K. Mollan, and C. Budhathoki Atazanavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 Ann Intern Med 154 2011 445 456
37. C.J. Cohen, J. Andrade-Villanueva, B. Clotet, J. Fourie, M.A. Johnson, and K. Ruxrungtham Rilpivirine versus efavirenz with two background nucleoside or nucleotide reverse transcriptase inhibitors in treatment-naive adults infected with HIV-1 (THRIVE): a phase 3, randomised, non-inferiority trial Lancet 378 2011 229 237
38. G.L. Colombo, V. Colangeli, B.A. Di, M.S. Di, C. Viscoli, and P. Viale Cost-effectiveness analysis of initial HIV treatment under Italian guidelines Clinicoecon Outcomes Res 3 2011 197 205
39. A.J. Brogan, J. Mrus, A. Hill, A.W. Sawyer, and E. Smets Comparative cost-efficacy analysis of darunavir/ritonavir and other ritonavir-boosted protease inhibitors for first-line treatment of HIV-1 infection in the United States HIV Clin Trials 11 2010 133 144
40. E.S. Daar, C. Tierney, M.A. Fischl, P.E. Sax, K. Mollan, and C. Budhathoki Atazamavir plus ritonavir or efavirenz as part of a 3-drug regimen for initial treatment of HIV-1 Ann Intern Med 154 2011 445 456
41. M. Stoll, C. Kollan, F. Bergmann, J. Bogner, G. Faetkenheuer, and C. Fritzsche Calculation of direct antiretroviral treatment costs and potential cost savings by using generics in the German HIV ClinSurv cohort PLoS One 6 2011 e23946
42. E.J. Beck, G. Harling, S. Gerbase, and P. DeLay The cost of treatment and care for people living with HIV infection: implications of published studies, 1999-2008 Curr Opin HIV AIDS 5 2010 215 224
43. C.E. Sloan, K. Champenois, P. Choisy, E. Losina, R.P. Walensky, and B.R. Schackman Newer drugs and earlier treatment: impact on lifetime cost of care for HIV-infected adults AIDS 26 2012 45 56